Sector pending / Pharmaceutical PreparationsUpdated 2026-05-10 22:07 UTC

FRA/RPD stock hub

FRA/RPD has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/RPDis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

19.2B

Frankfurt Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

FRA/RPD

In the news

Latest news · FRA/RPD

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E7.7

P25 n/aP50 n/aP75 n/a

Trailing P/E26.7

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC5.7

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/RPD market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

168

Groups with data

Currency

USD

Showing 168 of 168 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United Kingdom
Country code	DE
Employees	100
Enterprise value	EUR 29B
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Pharmaceutical Preparations
Last refreshed	2026-05-10
Market cap	EUR 19.2B
Price	EUR 42.4
Price currency	EUR
Rev Per Employee	21,172,466.89x
Sic	2834
Symbol	fra/RPD
Website	https://www.royaltypharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.74%
EV Earnings	40.44x
EV/EBIT	20.03x
EV/Sales	13.99x
Forward P/E	7.66x
P/B ratio	2.28x
P/E ratio	26.74x
P/S ratio	9.06x
PE Ratio3 Y	23.63x
PE Ratio5 Y	45.22x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	67.98%
Gross margin	114.99%
Gross Profit	EUR 2.4B
Gross Profit Growth	25.2%
Gross Profit Growth Q	19.07%
Gross Profit Growth3 Y	22.67%
Gross Profit Growth5 Y	9.79%
Net Income	EUR 717.2M
Net Income Growth	-24.31%
Net Income Growth Q	23.77%
Net Income Growth3 Y	35.58%
Net Income Growth5 Y	10.9%
Pretax Margin	55.68%
Profit Margin	33.87%
Profit Per Employee	EUR 7.2M
Roa5y	4.83
Roe5y	11.64
ROIC	5.75

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	54.99%
Cagr3y	13.42%
Div CAGR3	1.66%
EPS Growth	-22.57
EPS Growth Q	-2.83
EPS Growth3 Y	36.12
EPS Growth5 Y	9.38
OCF Growth	-3.28%
OCF Growth Q	20.45%
OCF Growth3 Y	-1.31%
OCF Growth5 Y	4.56%
Revenue Growth	7.83x
Revenue Growth Q	11.04x
Revenue Growth3 Y	1.15x
Revenue Growth5 Y	2.15x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	EUR 552.9M
Debt	EUR 7.8B
Debt Equity	EUR 0.92
Equity	EUR 8.4B
Interest Coverage	4.93
Net Cash	EUR -7.2B
Net Cash By Market Cap	EUR -37.69
Net Debt Equity	EUR 0.86
Tangible Book Value	EUR 4.8B
Tangible Book Value Per Share	EUR 11.23

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	5.1%
Dividend Growth	-2.39%
Dividend Growth Years	6%
Dividend per share	EUR 0.77
Dividend Years	7
Dividend Yield	1.83%
Ex Div Date	2026-02-20
Last Dividend	EUR 0.2
Payout Frequency	Quarterly
Payout Ratio	47.03%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	54.95%
200-day SMA	34.31
3Y total return	45.91%
50-day SMA	39.99
50-day SMA vs 200-day SMA	50over200
All Time High	44.6
All Time High Change	-4.94%
All Time High Date	2022-07-18
All Time Low	23.12
All Time Low Change	83.37%
All Time Low Date	2024-12-16
ATR	0.9
Ch YTD	29.14
High	42.4
High52	43
High52 Date	2026-05-04
High52ch	-1.41%
Low	42.4
Low52	27.77
Low52 Date	2025-05-27
Low52ch	52.67%
Ma50ch	6%
Price vs 200-day SMA	23.58%
RSI	61.69
RSI Monthly	74.34
RSI Weekly	76.87
Sharpe ratio	1.38x
Sortino ratio	2.42
Total Return	6.93%
Tr YTD	29.83
Tr1m	7.03%
Tr1w	-1.41%
Tr3m	13.06%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 1.4B
Operating Income Growth	-12.68
Operating Income Growth Q	18.5
Operating Income Growth3 Y	11.97
Operating Income Growth5 Y	1.66
Operating margin	67.98

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	435,893,986%
Net Borrowing	809,358,530
Shares Insiders	1.36%
Shares Institutions	83.13%
Shares Qo Q	0.18%
Shares Yo Y	-5.1%
Short Ratio	3.56

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	18x
Bv Per Share	13.1
Ch1m	7.03
Ch1w	-1.41
Ch1y	51.25
Ch3m	12.45
Ch3y	34.37
Ch6m	26.82
Change	2.44%
Change From Open	0
Close	41.39
Days Gap	2.44
Depreciation Amortization	3,266,349.6
Earnings Date	2026-05-06
EBIT	EUR 1.4B
EPS	EUR 1.65
F Score	4
Financing CF	-449,237,983
Fiscal Year End	December
Founded	1,996
Graham Number	25.78029
Graham Upside	-39.19
Investing CF	-2,251,666,914
Is Primary Listing	0
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Lynch Fair Value	EUR 17.28
Lynch Upside	-59.25
Ma150	35.51
Ma150ch	19.39%
Ma20	41.16
Ma20ch	3%
Net CF	-435,670,809
Open	42.4
P OCF Ratio	8.47
Payment Date	2026-03-10
Price Date	2026-05-08
Ptbv Ratio	3.98
Relative Volume	14.12x
Revenue	2,117,246,689x
SBC By Revenue	11.88x
Share Based Comp	251,425,066
Tr6m	28.22%

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

FRA/RPD dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.8%

$0.77 annual per share

Payout ratio

+47.0%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

n/a

6 consecutive years of growth

Total shareholder yield

+6.9%

Next ex-dividend date: 2026-02-20

Performance

FRA/RPD stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/RPD?

Insider, institutional, and short-interest positioning.

Institutional ownership

+83.1%

Share of float held by funds and institutions

Insider ownership

+1.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/RPD momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

61.7

Neutral momentum band

Price vs 200-day MA

+23.6%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

1.38

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/RPD

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/RPD stock rating?

fra/RPD is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/RPD analysis?

The full report lives at /stocks/fra/RPD/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/RPD?

The latest report frames fra/RPD around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/RPD page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.